Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

SRR1313099

· A

ca335550-d9bd-5c86-ac84-39218b690845

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYOGENESIS+0.230
  • ALLOGRAFT_REJECTION+0.150
  • BILE_ACID_METABOLISM+0.110
  • WNT_BETA_CATENIN_SIGNALING+0.080
  • IL6_JAK_STAT3_SIGNALING+0.070
  • UV_RESPONSE_DN+0.030
  • ADIPOGENESIS+0.010
  • XENOBIOTIC_METABOLISM+0.000
  • KRAS_SIGNALING_DN-0.010
  • KRAS_SIGNALING_UP-0.010

Top 10 suppressed

  • E2F_TARGETS-0.700
  • MYC_TARGETS_V1-0.660
  • G2M_CHECKPOINT-0.650
  • MYC_TARGETS_V2-0.630
  • MTORC1_SIGNALING-0.570
  • UNFOLDED_PROTEIN_RESPONSE-0.480
  • GLYCOLYSIS-0.420
  • ESTROGEN_RESPONSE_LATE-0.370
  • ANDROGEN_RESPONSE-0.350
  • MITOTIC_SPINDLE-0.350

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1313120
breast-umap@18
A0.924
2SRR2016932
head-neck@1
0.898
3TCGA-55-A4DG-01A-11R-A24H-07
lung-landscapes@6
cohortA10.887
4TCGA-NJ-A55A-01A-11R-A262-07
lung-landscapes@6
cohortA10.886
520020052.LumA
breast-umap@18
A0.871
6s0122234
melanoma-umap@29
0.866
7TCGA-97-A4M1-01A-11R-A24X-07
lung-landscapes@6
cohortA10.866
8MNG60
mng-umap@100
0.865
9TCGA-97-A4M2-01A-12R-A24X-07
lung-landscapes@6
cohortA10.862
10BS_A87NPZAP
medullo-epn-umap@date-based
MedMedulloblastoma0.854

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 7 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYOGENESIS0.230Inavolisib— uncovered
ALLOGRAFT_REJECTION0.150Idelalisib— uncovered
BILE_ACID_METABOLISM0.110Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.080Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.070Inavolisib— uncovered
UV_RESPONSE_DN0.030Inavolisib— uncovered
ADIPOGENESIS0.010Inavolisib— uncovered